AMTI Applied Molecular Transport Inc.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
AMT-101 (MARKET)
Ulcerative colitis
|
Phase 2
Phase 2
|
Phase 2 trial to be initiated by end of 2020.
|
|
AMT-101 (CASTRO)
Rheumatoid arthritis
|
Phase 2
Phase 2
|
Phase 2 trial to be initiated 1H 2021.
|
|
AMT-101 (LOMBARD)
Ulcerative colitis
|
Phase 2
Phase 2
|
Phase 2 commencement of dosing announced August 27, 2020.
|
|
AMT-101 (FILLMORE)
Pouchitis
|
Phase 2
Phase 2
|
Phase 2 trial planned for 2020.
|
Latest News
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:30 p.m. ET.
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.
AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]
-
View Full Article Hide Full Article
- Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including inflammatory bowel diseases and rheumatoid arthritis -
- Announced dosing of first patient in Phase 2 monotherapy trial (LOMBARD) evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severe ulcerative colitis -
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020.
"We continue to make important progress in the development of our differentiated oral biologic drug candidates in a number of indications," said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. "We recently advanced oral AMT-101 into a Phase 2 monotherapy trial in patients with ulcerative colitis (UC). In addition, we continue the planned expansion of this comprehensive clinical program with two additional Phase 2 trials of AMT-101 in combination with anti-TNFα therapy in biologic-naïve patients with moderate to severe UC and as a monotherapy in patients with pouchitis, both initiating by year-end. We are also looking forward to the initiation of the fourth Phase 2 trial for AMT-101 in combination with anti-TNFα in rheumatoid arthritis patients who are partially responding to anti-TNFα therapy. Furthermore, given the broad potential of our technology platform as an engine for the development of novel oral biologics, we continue to work on expanding our deep pipeline into additional indications and therapeutic areas and look forward to sharing updates on our progress."
Recent Business Highlights
- Announced dosing of the first patient in the LOMBARD Phase 2 monotherapy trial evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severe UC
- Successfully manufactured AMT-101 and AMT-126 clinical biologic drug supply at AMT's internal GMP manufacturing facility
- Announced publication of preclinical data demonstrating potential of AMT-101 for inflammatory diseases in The Journal of Immunology (November 2020 issue)
Anticipated Upcoming Milestones
- Initiate the remaining Phase 2 trials for oral AMT-101:
- MARKET clinical trial of oral AMT-101 in combination with anti-TNFα, in biologic-naïve, moderate to severe UC patients by year-end
- FILLMORE clinical trial of oral AMT-101 for the treatment of pouchitis by year-end
- CASTRO clinical trial of oral AMT-101 in combination with anti-TNFα for the treatment of rheumatoid arthritis in 1H 2021
- Anticipate top-line data readouts from the four AMT-101 Phase 2 trials beginning in 2H 2021 and into 1H 2022
- File IND/CTA for AMT-126, a gastrointestinal (GI)-selective oral fusion of hIL-22, to treat serious diseases associated with intestinal epithelial (IE) barrier defects by year-end
Financial Results for the Third Quarter Ended September 30, 2020
Research and development (R&D) expenses. Total R&D expenses for the third quarter of 2020 were $13.4 million, compared to $6.9 million for the same period in 2019. The increase was primarily due to higher expenses associated with clinical trials, preclinical studies, materials, compensation, and facilities related expenses, offset by a decrease in contract manufacturing due to internal capabilities.
General and administrative (G&A) expenses. Total G&A expenses for the third quarter of 2020 were $3.4 million, compared to $1.0 million for the same period in 2019. The increase was primarily due to an increase in personnel costs and professional fees.
Net loss. Net loss for the third quarter of 2020 was $16.8 million, compared to $7.9 million for the third quarter of 2019.
Cash, cash equivalents, and investments. As of September 30, 2020, cash, cash equivalents, and investments were $147.3 million.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local GI tissue or enter systemic circulation to precisely address the relevant biology of a disease.AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements including statements relating to AMT's plans, expectations, forecasts and future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding AMT's technology platform, statements regarding AMT's Phase 2 clinical trials for AMT-101 including the timing of such trials, the timing of the filing of IND/CTA for AMT-126, AMT's ability to leverage its technology to expand its pipeline, presentations regarding AMT-101's Phase 1b dataset, and AMT-101 top-line data readouts including the timing of such readouts. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our technology platform to build a pipeline of product candidates; uncertainty of developing biologic therapeutics; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercializing of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; potential delays and disruption resulting from the COVID-19 pandemic; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in AMT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2020, and AMT's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.Applied Molecular Transport Inc.
Condensed Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)September 30, December 31, 2020 2019(*) Assets Current assets: Cash and cash equivalents $ 11,314 $ 12,727 Short-term investments 135,940 19,676 Prepaid expenses 1,816 532 Deferred offering costs — 366 Other current assets 79 152 Total current assets 149,149 33,453 Property and equipment, net 8,437 4,091 Long-term investments — 249 Restricted cash 108 108 Other assets 127 632 Total assets $ 157,821 $ 38,533 Liabilities, convertible preferred stock and stockholders' equity (deficit) Current liabilities: Accounts payable $ 2,705 $ 2,666 Accrued expenses 4,692 1,315 Deferred rent, current 65 13 Capital lease obligations, current 229 42 Total current liabilities 7,691 4,036 Deferred rent 473 526 Capital lease obligations 463 58 Total liabilities 8,627 4,620 Commitments and contingencies Series A convertible preferred stock, $0.0001 par value, 0 shares authorized, issued, and outstanding as of September 30, 2020 and 5,157,213 shares authorized, issued and outstanding, as of December 31, 2019; liquidation value of $0 as of September 30, 2020 and $33,000 as of December 31, 2019 — 32,826 Series B convertible preferred stock, $0.0001 par value, 0 shares authorized, issued, and outstanding as of September 30, 2020 and 3,992,919 shares authorized, issued and outstanding as of December 31, 2019; liquidation value of $0 as of September 30, 2020 and $31,025 as of December 31, 2019 — 30,921 Series C convertible preferred stock, $0.0001 par value, 0 shares authorized, issued, and outstanding as of September 30, 2020 and 4,816,160 shares authorized, issued and outstanding as of December 31, 2019; liquidation value of $0 as of September 30, 2020 and $41,949 as of December 31, 2019 — 41,868 Stockholders' equity (deficit): Common stock, $0.0001 par value, 450,000,000 and 32,000,000 shares authorized as of September 30, 2020, and December 31, 2019, respectively; 34,880,411 and 7,360,738 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 3 1 Additional paid-in capital 269,437 1,078 Accumulated other comprehensive income 31 13 Accumulated deficit (120,277 ) (72,794 ) Total stockholders' equity (deficit) 149,194 (71,702 ) Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 157,821 $ 38,533 (*) Derived from audited Financial Statements.
Applied Molecular Transport Inc.
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 13,395 $ 6,890 $ 39,185 $ 17,756 General and administrative 3,428 1,008 8,404 2,510 Total operating expenses 16,823 7,898 47,589 20,266 Loss from operations (16,823 ) (7,898 ) (47,589 ) (20,266 ) Interest income, net 59 36 187 107 Other expense, net (29 ) (3 ) (81 ) (15 ) Net loss $ (16,793 ) $ (7,865 ) $ (47,483 ) $ (20,174 ) Net loss per share, basic and diluted $ (0.48 ) $ (1.07 ) $ (2.53 ) $ (2.74 ) Weighted-average shares of common stock outstanding, basic and diluted 34,767,308 7,360,738 18,770,153 7,360,738 Comprehensive loss: Net loss $ (16,793 ) $ (7,865 ) $ (47,483 ) $ (20,174 ) Other comprehensive income (loss): Unrealized gains on investments 29 3 37 3 Amounts recognized for net realized gains included in net loss — — (19 ) — Total comprehensive loss $ (16,764 ) $ (7,862 ) $ (47,465 ) $ (20,171 ) Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected] -
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical officer of AMT, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:00 p.m. ET / 5:00 p.m. GMT.
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected] -
View Full Article Hide Full Article
- AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue -
- Demonstrates minimal systemic exposure of hIL-10 while driving induction of an anti-inflammatory profile correlated with hIL-10 in rodent and non-human primate models -
- Acts on macrophage cells and lymphocytes within intestinal tissue leading to efficacy outcomes in colitis models -
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the unique mechanism of action of AMT-101 and preclinical data supporting its potential as a treatment for ulcerative colitis (UC), and other inflammatory diseases, have been published in The Journal of Immunology. The article entitled, "A Novel Fusion of Interleukin-10 Engineered to Traffic Across Intestinal Epithelium to Treat Colitis" was published in the November 2020 online edition of The Journal of Immunology.
The research published in The Journal of Immunology highlights how AMT's proprietary technology platform exploits existing natural cellular trafficking pathways to actively transport therapeutics through the intestinal barrier directly into the underlying immune-rich milieu of the lamina propria. IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation. However, clinical utilization of IL-10 to treat inflammation and immune-dysregulation has been limited due to side effects associated with systemic administration.
"Our breakthrough platform technology enables the active transport of oral biologics by solving the long-standing industry challenge of transporting large, biologically-active molecules efficiently across the intestinal barrier," said Randall Mrsny, Ph.D., chief scientific officer and co-founder of AMT. "Our technology platform is based on native, active vesicular transcytosis mechanisms to rapidly and efficiently traverse intestinal epithelial cells. Once across this epithelia barrier and in the underlying intestinal lamina propria, AMT-101 targets local macrophages and lymphocytes to activate cell signaling pathways, inducing tissue and circulating markers demonstrating IL-10 mechanism of action through cognate receptor engagement and down-stream signaling. Importantly, we continue to leverage our technology platform to be a robust engine for the design and development of a wide range of oral biologic therapeutics."
In vitro and in vivo characterization of AMT-101 demonstrated its ability to efficiently cross the human intestinal epithelium by an active, receptor-mediated vesicular transcytosis process, activating IL-10 receptor signaling to increase cellular phospho-STAT3 (pSTAT3) levels in macrophage cells. In models of induced colitis, AMT-101 was able to rectify pathologic changes by suppressing pro-inflammatory markers of disease while inducing anti-inflammatory cytokines, both locally in the intestinal tissue as well as in plasma.
"Our preclinical data has also shown that oral hIL-10 can be targeted to the intestinal lamina propria with minimal systemic PK, suggesting that we may be able treat IBD patients with fewer toxicities than previously observed following the systemic administration of this potent cytokine," said Tahir Mahmood, PhD, chief executive officer and co-founder of AMT. "We have evaluated AMT-101 in active ulcerative colitis patients in a Phase 1b study and demonstrated reductions in objective clinical measures of intestinal inflammation such as fecal calprotectin and histopathologic scores, as well as systemic indicators of inflammation such as C-reactive protein, after just 14 days of treatment. We are excited about our ongoing and planned Phase 2 trials for AMT-101 in IBD and rheumatoid arthritis and will continue to leverage the platform to build our pipeline of differentiated oral biologic therapeutics."
About AMT-101
AMT-101 is a GI-selective, oral fusion of hIL-10 and its proprietary carrier molecule, which is currently being developed in four Phase 2 clinical trials in inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is designed to cross the intestinal epithelium (IE) barrier with limited entry into the bloodstream, thereby focusing hIL-10 in the lamina propria of the gastrointestinal (GI) tissue and, therefore, potentially avoiding the side effects observed with systemic administration. By design, AMT-101 is actively transported through the IE barrier into the GI tissue, the primary site of inflammation in UC.About Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory autoimmune disease of the GI tract with approximately 2.2 to 2.4 million patients in the United States and Europe according to a 2014 report. Current therapies for UC have significant adverse side effects including systemic immunosuppression, increased incidence of opportunistic and rare infections, and increased risk for cancer. Furthermore, approximately half of UC patients will relapse in any given year, including a minority with frequently relapsing or chronic, continuous disease and approximately 15.6% of UC patients will undergo surgery within 10 years of diagnosis, with 20% to 30% of patients ultimately proceeding to surgical colectomy. In addition, UC may have a profound effect on quality of life, including mental health consequences, and a significant minority of patients become incapable of work due to disease. Thus, there remains a significant and unmet clinical need to better manage UC with safer and more effective oral therapies.About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local GI tissue or enter systemic circulation to precisely address the relevant biology of a disease.AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or AMT's future plans, strategy and performance. Such statements include, but are not limited to, the potential of, and expectations regarding AMT's technology platform and AMT-101, statements regarding AMT's Phase 2 clinical trials for AMT-101 including the timing of such trials, AMT's ability to leverage its technology to expand its pipeline, and the unmet clinical need to better manage UC. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including those more fully described under the section entitled "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]Media Contacts:
Sylvia Wheeler
Principal, Wheelhouse Life Science Advisors
[email protected]Alexandra Santos
Senior Partner, Wheelhouse Life Science Advisors
[email protected] -
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical officer of AMT, will participate in a fireside chat during the Jefferies Next Generation IBD Therapeutics Virtual Summit which will be webcasted on Wednesday, September 23, 2020 at 8:00 a.m. ET.
The webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing oral biologic product candidates in patient-friendly tablet and capsule forms that are designed for either targeting local gastrointestinal (GI) tissue or entering systemic circulation to precisely address the relevant biology of a disease. AMT is building a portfolio of oral product candidates based on its technology platform including its lead product candidate, AMT-101, an oral GI-selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). AMT further plans to initiate Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications. AMT's technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics, with potentially significant advantages over existing marketed and development-stage drugs.Contacts:
Sylvia Wheeler
Principal, Wheelhouse Life Science Advisors
[email protected]Alexandra Santos
Senior Partner, Wheelhouse Life Science Advisors
[email protected]